19th week of 2019 patent applcation highlights part 12 |
Patent application number | Title | Published |
20190134123 | NOVEL SYSTEM AND METHOD FOR MICROBIOME PROFILING AND MODULATION BY MEANS OF CANNABIS ADMINISTRATION - Novel means and methods for personalized diagnosing and profiling health status in mammalian subjects, as well as optimization of pharmacological treatments for patients, based on profiling and modulating of patient-derived microbiota. Combined method and system for selecting the optimal cannabinoid-based treatment modality for a range of cancerous and infective diseases and disorders by modulating said subject microbiome. | 2019-05-09 |
20190134124 | Herbal composition for treatment and management of infectious diseases and method of preparation thereof - Herbal composition for treatment and management of Infectious diseases and method of preparation are disclosed herein. The disclosed composition including herbs and bhasmas may be used to treat Infectious diseases such as bacterial infection, fungal infection, viral infections, Pharyngitis, Laryngitis and Bronchitis etc. The method disclosed herein may be used as the main line of treatment or as supportive medication. | 2019-05-09 |
20190134125 | ENHANCED SMOKABLE THERAPEUTIC CANNABIS PRODUCT AND METHOD FOR MAKING SAME - An enhanced smokable | 2019-05-09 |
20190134126 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING RESPIRATORY DISEASE COMPRISING EXTRACT OF JUSTICIA PROCUMBENS L. - The present invention relates to a pharmaceutical composition for preventing or treating respiratory disease, which comprises an alcohol or organic solvent extract of | 2019-05-09 |
20190134127 | METHODS FOR MANUFACTURING AND PURIFYING DRIED BURDOCK SEED EXTRACT - A method for manufacturing a dried burdock seed extract in order to manufacture the dried burdock seed extract rich in arcitigenin is disclosed. The method includes: sequentially mixing a raw material, water and an extractant to obtain a mixture. The mixture includes 7-14 vol % of the raw material, 8-40 vol % of water and 50-84 vol % of the extractant being a 95% aqueous ethanol solution. The raw material is then extracted at a boiling condition for 20-180 minutes, followed by concentration and centrifugation to obtain the dried burdock seed extract. A method for purifying the dried burdock seed extract is also disclosed. | 2019-05-09 |
20190134128 | METHOD FOR PRODUCING CELASTROL AND PENTACYCLIC TRITERPENE DERIVATIVES - The present invention relates to a method for producing a crude extract enriched in pentacyclic triterpenes, including celastrol, from cells of a plant from the Celastraceae family; an enriched crude extract that can be obtained using such a method; therapeutic applications of such an extract; and pharmaceutical and dermocosmetic compositions containing such an extract. | 2019-05-09 |
20190134129 | METHOD FOR ALLEVIATING ULTRAVIOLET DAMAGE WITH ETHYL ACETATE-EXTRACTED PRODUCT OF SEDUM FORMOSANUM - A method for alleviating ultraviolet damage includes administering to a subject in need thereof a composition containing an ethyl acetate-extracted product of | 2019-05-09 |
20190134130 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING LIVER DISEASES, CONTAINING LICORICE EXTRACT CONTAINING GLYCYRRHIZIN AND LIQUIRITIN - Disclosed is a composition containing a licorice extract comprising glycyrrhizin and liquiritin at a content ratio of 1.5 to 1.8:1, obtained by performing extraction on licorice, adding an excipient and performing spray drying. The composition containing the licorice extract can be efficiently used as a pharmaceutical composition for the prevention or treatment of liver disease or a food composition for the improvement of liver function in the pharmaceutical and food industry fields. | 2019-05-09 |
20190134131 | NUTRITION BLEND FOR HEALTH BENEFITS IN ANIMALS - Methods and compositions for providing a health benefit to an animal using a nutrient blend. In one embodiment, the method can comprise orally administering a composition comprising at least four of the nutrients selected from the group of walnut, maitake mushroom extract, EGCG, turmeric root powder, lycopene, taurine, EPA, and DHA to the animal. | 2019-05-09 |
20190134132 | NUTRITION BLEND FOR HEALTH BENEFITS IN ANIMALS - A method of minimizing fat accumulation in a growing animal without limiting caloric intake or preventing or treating obesity in an animal, the method comprising orally administering a ketogenic diet and a nutrient blend to the animal. The nutrient blend can include at least four nutrients selected from the group consisting of walnut, maitake mushroom extract, EGCG, turmeric root powder, lycopene, taurine, EPA, and DHA to the animal. | 2019-05-09 |
20190134133 | COMPOSITION FOR REDUCING ANXIETY IN A COMPANION ANIMAL - The present invention provides a composition for reducing anxiety in a companion animal, particularly a feline. Such a composition is based on an extract of an ingredient mixture including catnip, valerian root, black tea, thyme, mango and, optionally, one or more of banana and slippery elm, the composition further comprising lavender. Methods of manufacture and use are further described. | 2019-05-09 |
20190134134 | METHOD FOR REDUCING THE CONTENT OF HEAVY METALS IN BLOOD AND IMPROVING THE PULMONARY FUNCTION USING GREEN PEAR FRUITLET EXTRACT - The present invention provides a method for reducing the content of heavy metals in blood and improving the pulmonary function using green pear fruitlet extract. The green pear fruitlet extract can effectively reduce the content of harmful heavy metals in human body to prevent the harmful effects of heavy metals, and improve forced vital capacity and the peak expiratory flow of humans to reduce the respiratory resistance and increase the expiratory flow. The green pear fruitlet extract is prepared by extracting green pear fruitlet using water, alcohol, or a mixture of water and alcohol as a solvent. | 2019-05-09 |
20190134135 | COMPOSITION FOR COOLING SKIN COMPRISING PHELLODENDRON BARK EXTRACT, METHOD OF PREPARING THE SAME, TOPICAL COMPOSITION COMPRISING THE SAME AND DERMATOLOGICALLY ACCEPTABLE CARRIER, AND METHOD OF COOLING SKIN BY APPLYING THE SAME - Provided are a composition for cooling skin comprising a Phellodendron bark extract, a method of preparing the composition, a skin-improving product comprising the composition and a method of cooling skin by applying the composition to a skin of a subject, wherein the skin needs cooling. The composition prevents a burning sensation in the skin and under the skin and reduces heat generated under the skin and on the skin. The composition includes a Phellodendron bark extract as a main ingredient and further includes an extract of one or more selected from the group consisting of Anemarrhena asphodeloides, Scutellaria baicalensis, Paeonia lactiflora, Dictamnus dasycarpus, Alumen, Dryobalanops aromatic and Mentha arvensis. | 2019-05-09 |
20190134136 | Pharmaceutical Composition on the Basis of Stachytarpheta SP., a Process for obtaining the same and its use for Treating Vitiligo - This invention generally refers to the process to obtain a compound and a standard pharmaceutical product from one or more parts of plant of the | 2019-05-09 |
20190134137 | SYSTEM AND METHOD FOR PROCESSING RAW SUGARCANE MAXIMIZING THE PRESERVATION OF POLICOSANOLS DURING PRODUCTION OF A SHELF STABILE POTABLE CHOLESTEROL-REDUCING PRODUCT - A method/process is provided for extracting and processing sugarcane juice from sugarcane stalks to produce a shelf-stable natural juice product preserving policosanols naturally-occurring in raw sugarcane sticks. The method includes steps of: providing sugarcane stalks having a high sucrose level; extracting sugarcane juice from the sugarcane stalks using a roller mill apparatus; filtering the extracted sugarcane juice through a screen filter; stabilizing the pH of the juice in a non-acidic solution of calcium hydroxide to a pH level in the range of 7.4 to 7.6; flocculating the sugarcane juice with a mixture of water and at least one natural flocculate product; evaporating the sugarcane juice to form a sugarcane juice concentrate having a Brix in the range of 50° Bx to 60° Bx; and extracting the sugarcane juice concentrate from the evaporator, while maintaining a maximum sugarcane juice temperature never exceeding 70° C. throughout the process. | 2019-05-09 |
20190134138 | SKIN SENSITIZER DELIVERY SYSTEM - A skin-sensitizing formulation is provided in an edible, softgel pill. A person engaged in a sexual activity bites down on the pill, thereby effectuating the oral release of the skin-sensitizing formulation. This allows the skin-sensitizing formulation to be spread to a sexual partner, on any part of the skin or sexual region of the body preferably through oral contact with the partner. The skin-sensitizing substance is spread to the partner directly on the skin or through oral contact or beneath a condom worn by the partner. The skin-sensitizing formulation may include an essential mint oil, analog or derivative, and may further includes an enhancer, rubefacient, counterirritant, anesthetic, k-opioid receptor activator, or TRPM8 activator. Various inactive ingredients are also disclosed. | 2019-05-09 |
20190134139 | FERMENTED PENNISETUM EXTRACT - The invention provides a fermented | 2019-05-09 |
20190134140 | ORALLY ADMINISTERED COMPOSITION FOR TREATING CYSTIC FIBROSIS, COPD, ASTHMA AND OTHER INFLAMMATORY CONDITIONS - The invention relates to a new orally administered composition, which in present embodiments is a standardized phytochemical formulation but other embodiments may contain designed molecules. This formulation is capable of suppressing inflammation in a variety of disease conditions having an underlying inflammatory component, including but not limited to cystic fibrosis, COPD, asthma, and pancreatitis. It is an objective of the invention to provide a non-toxic therapy, which exhibits anti-oxidant anti-inflammatory properties without deleterious side effects. | 2019-05-09 |
20190134141 | METHODS OF DOWNREGULATING TRANSLOCATED ONCOGENE EXPRESSION USING BROMODOMAIN INHIBITORS - Disclosed herein are novel methods and compositions useful for inhibiting interaction between a bromodomain protein and an immunoglobulin (Ig) regulatory element. The methods and compositions are particularly useful for downregulating expression of an oncogene translocated with an Ig locus, as well as for treating a cancer (e.g., hematological malignancy) characterized by increased expression of an oncogene which is translocated with an Ig locus. Also disclosed herein are methods and assays for identifying agents that interfere with binding of bromodomain proteins to Ig regulatory elements, as well as methods and assays for identifying inhibitors of bromodomain | 2019-05-09 |
20190134142 | MULTI-FACTOR HAIR GROWTH FORMULATION - A synergistic, multi-factor hair growth formulation and its method of use are described. A plurality of synthetic peptides and proteins are selected to maximize efficacy at discrete stages of the anagenic growth phase of a hair follicle, and these compounds may be further coated to promote uptake into the skin and/or hair root. The formulation itself is topical, so as to allow for direct, selective application alone or in combination with mechanical or energetic delivery techniques. | 2019-05-09 |
20190134143 | THERAPEUTIC PEPTIDES FOR EXCITATORY NEUROTOXICITY-RELATED INJURIES - There is provided in the present application a peptide comprising the amino acid sequence of YEKLLDTEI (SEQ ID NO: 1) or a functional variant thereof. The peptide is an active peptide for the treatment of a central nervous system injury. The present application also provides a chimeric peptide comprising an active peptide and an internalization peptide. The present application also provides a pharmaceutical composition comprising the active peptide or the chimeric peptide, as well as medical use of the active peptide or the chimeric peptide. | 2019-05-09 |
20190134144 | METHODS FOR TREATING AUTISM SPECTRUM DISORDER AND ASSOCIATED SYMPTOMS - The present disclosure relates to compositions and methods for treating autism spectrum disorder (ASD) by restoring an ASD patient's gut microbiota. These methods can be used with ASD patient with or without ongoing gastrointestinal symptoms. Provided here is a method for ASD treatment in a subject in need thereof comprising or consisting essentially of administering a therapeutic composition comprising a fecal microbe or a fecal microbiota preparation to the subject. Also provided here is a method comprises administering an antibiotic to a human subject; subjecting the human subject to a bowel cleanse; and administering purified fecal microbiota to the human subject. Further provided are evaluation and quantitative characterization of patient symptom improvements upon treatment described here. | 2019-05-09 |
20190134145 | METHOD FOR TREATING COGNITIVE DYSFUNCTION - The present invention provides compositions and methods for treating cognitive impairment or dysfunction in a subject. In particular, the present invention provides a method for using a composition comprising an angiotensin-(1-7) receptor agonist to treat cognitive dysfunction or impairment that is due to a various clinical conditions including, but not limited to, those associated with increase in inflammation, cytokine production, increases in reactive oxygen species, changes in expression of brain inflammatory related genes and/or in the expression of genes involved in learning and memory within the central nervous system of a subject. | 2019-05-09 |
20190134146 | METHODS COMPRISING DESMOPRESSIN - The present disclosure is directed to reducing nocturnal voids by administering a dose of desmopressin over a minimum treatment period compared to before administration, and maintaining or improving the reduction of nocturnal voids over the minimum treatment period. | 2019-05-09 |
20190134147 | TFPI INHIBITORS AND METHODS OF USE - The invention provides peptides that bind Tissue Factor Pathway Inhibitor (TFPI), including TFPI-inhibitory peptides, and compositions thereof. The peptides may be used to inhibit a TFPI, enhance thrombin formation in a clotting factor-deficient subject, increase blood clot formation in a subject, treat a blood coagulation disorder in a subject, purify TFPI, an identify a TFPI-binding compound. | 2019-05-09 |
20190134148 | COMBINATION THERAPY - The present invention relates to a combination comprising a proteasome inhibitor and a cyclic peptide that comprises an exposed Arg-Gly-Asp (RGD) moiety; wherein the combination is formulated for oral administration of both the proteasome inhibitor and cyclic peptide components. In particular, the present invention relates to a combination comprising a proteasome inhibitor selected from the group consisting of: a boronate, anepoxyketone, a peptide aldehyde and a β-lactone protease inhibitor; and a cyclic peptide that comprises an exposed Arg-Gly-Asp (RGD) moiety; wherein the combination is formulated for oral administration of both the proteasome inhibitor and cyclic peptide components. More particularly, the present invention relates to a combination comprising a proteasome inhibitor selected from the group consisting of: bortezomib, delanzomib, ixazomib, carfilzomib, oprozomib, MG132 and marizomib; and a cyclic peptide that comprises an exposed Arg-Gly-Asp (RGD) moiety; wherein the combination is formulated for oral administration of both the proteasome inhibitor and cyclic peptide components. | 2019-05-09 |
20190134149 | Compositions and Methods for Inhibiting Tumor-Induced Immune Suppression - It has been discovered that the cyclic peptide EnnA inactivates the Hsp90 chaperone pathway, but without activating an extensive heat shock response and overexpression of anti-apoptotic proteins. Mechanistically distinct, EnnA inhibits Hsp90 and destabilize PDL-1 and IDO, two major immune checkpoints mediating tumor-induced immune suppression. The provided herein show that EnnA profoundly modulates the cytokine signature of cancer cells and promotes a cytokine profile that favors an immune attack on tumor cells. This translates into highly efficacious anti-tumor activity in vivo, which, when combined with a single dose of chemotherapy, completely reduced the tumor burden in experimental animals and instilled highly efficient immune memory against the primary tumor. | 2019-05-09 |
20190134150 | THERAPEUTIC METHODS FOR EXCITATORY NEUROTOXICITY-RELATED INJURIES - There is provided in the present application a peptide comprising the amino acid sequence of YEKLTTLDTGGV (SEQ ID NO: 1) or a functional variant thereof. The peptide is an active peptide for the treatment of a central nervous system injury. The present application also provides a chimeric peptide comprising an active peptide and an internalization peptide. The present application also provides a pharmaceutical composition comprising the active peptide or the chimeric peptide, as well as medical use of the active peptide or the chimeric peptide. | 2019-05-09 |
20190134151 | ANTIBACTERIAL COMPOSITIONS, METHODS OF MAKING AND USE THEREOF - Compositions and methods for reducing the growth of and/or preventing the formation of a microbial biofilm are disclosed. The composition comprises an antimicrobial SMR peptide comprising an HIV-1 SMRwt peptide and a cell penetrating peptide (CPP) domain. In some embodiments, the composition further comprises one or more other antimicrobial peptides (AMPs), antibiotics, matrix-inhibiting compounds, matrix-disaggregating compounds, quorum sensing inhibitors, or a combination thereof. In other embodiments, the compositions are used for impregnating or coating an article and/or material surface with the composition to render it less prone to microbial infections. | 2019-05-09 |
20190134152 | TREATMENT OF A SUBTYPE OF ASD - The present invention is directed to a pharmaceutical composition comprising an Nrf2-inhibitor. Likewise, the present invention is directed to a pharmaceutical composition for use in the treatment of ASD in a patient, comprising: determining whether the patient suffers from ASD subtype 1 and administering a therapeutically effective amount of an Nrf2-inhibitor if the patients suffers from ASD subtype 1, wherein determining whether the patient suffers from ASD subtype 1 comprises administering the patient an Nrf2-activator and identifying the patient as suffering from ASD subtype 1 if he shows a negative response. | 2019-05-09 |
20190134153 | IMMUNOMODULATORY EFFECT OF INHALED KINASE INHIBITOR PEPTIDES IN LUNG - The described invention provides a method of treating a subject that is in an immunotolerant state with regard to an immune stimulating agent that is no longer therapeutically effective for treating a disease, disorder or condition of lung. The method includes the steps, in order, of (a) administering (1) a first pharmaceutical formulation formulated for delivery by inhalation containing an immunomodulatory amount of a kinase-inhibiting peptide, and (b) then administering a second pharmaceutical formulation containing a therapeutic amount of the immunostimulatory agent. The the method is effective to resensitize the subject to the immune stimulating agent so that the subject is once again immunoresponsive to it upon its subsequent administration. | 2019-05-09 |
20190134154 | GPNMB COMPOSITIONS FOR TREATMENT OF SKIN WOUNDS - A method for treating a skin wound of a subject is described. The method includes contacting the skin wound with a therapeutically effective amount of a wound healing composition comprising glycoprotein nonmelanoma clone B (GPNMB) protein, an active peptide fragment thereof, a GPNMB analog, a GPNMB potentiating agent, or a combination thereof. | 2019-05-09 |
20190134155 | COMBINED USE OF A VECTOR ENCODING A MODIFIED RECEPTOR AND ITS EXOGENOUS AGONIST IN THE TREATMENT OF SEIZURES - The invention provides methods and materials for treating a seizure disorder such as epilepsy in a patient which employ a vector encoding a modified receptor, the so-called “DREADD” receptor being characterised by (i) a decreased responsiveness to its endogenous activating ligand (ii) a retained or enhanced responsiveness to an exogenous agonist. The modified receptor is expressed in neurons of a seizure focus in brain of the patient, and an exogenous agonist is administered which activates the modified receptor to reversibly alters the excitability of the neurons in the seizure focus leading to synaptic silencing or other inhibition. | 2019-05-09 |
20190134156 | TISSUE PROTECTIVE PEPTIDES FOR PREVENTING AND TREATING DISEASES AND DISORDERS ASSOCIATED WITH TISSUE DAMAGE - Provided herein are peptides and peptide analogs that have tissue protective activities. The peptides and peptide analogs are useful in preventing and treating a variety of diseases and disorders associated with tissue damage. | 2019-05-09 |
20190134157 | ANTIBACTERIAL AGENT FOR TREATING INFECTIOUS DISEASES OF BACTERIAL ORIGIN - The invention relates to medicine, namely to the antimicrobial agent for the treatment of infectious bacterial diseases including hospital infections and drug-resistant TB which represents the ion nanostructured complex (INSC) synthesized from carbohydrates proteins and/or polypeptides (albumins, interleukins, interferons, signaling proteins, etc), which are to enhance the antimicrobial activity in vivo, by activating immune cells that contain at least one terminal amino acid such as Phe, Ala, Val, Ala, Leu, Ile, and others with electron-donor functional groups, iodine and halides of the alkali and alkaline earth elements in the fourth stage at a certain ionic strength; an antibacterial agent increases: the susceptibility of bacteria, including antibiotic-resistant, to antibiotics; activity of monocytes and macrophages; efficiency of antibiotic treatment of hospital infections and drug-resistant TB; it also has antiviral activity, stimulates hematopoietic function of bone marrow; has an antitumor effect and radioprotective properties; in acceptable concentrations of components can be used as non-pharmaceutical agent (BAFS or parapharmaceutical); is presented in the pharmacological form suitable for parenteral, oral, external, or other application. INSC has the formula [{(Ln(MeI3)+)y[Me(Lm)I]+x}(Cl−)y+x+k] with M=30-300 kDa. | 2019-05-09 |
20190134158 | Method of deliverying gonadotropin releasing hormone or an analogue thereof into a lumen of the intestinal tract using a swallowable drug delivery device - Embodiments of the invention provide swallowable devices, preparations and methods for delivering drugs and other therapeutic agents within the GI tract. Many embodiments provide a swallowable device for delivering the agents. Particular embodiments provide a swallowable device such as a capsule for delivering drugs into the intestinal wall or other GI lumen. Embodiments also provide various drug preparations that are configured to be contained within the capsule, advanced from the capsule into the intestinal wall and degrade to release the drug into the bloodstream to produce a therapeutic effect. The preparation can be operably coupled to delivery means having a first configuration where the preparation is contained in the capsule and a second configuration where the preparation is advanced out of the capsule into the intestinal wall. Embodiments of the invention are particularly useful for the delivery of drugs which are poorly absorbed, tolerated and/or degraded within the GI tract. | 2019-05-09 |
20190134159 | AMYLIN ANALOGUES - The present invention relates to amylin analogues and to their use in the treatment or prevention of a variety of diseases, conditions or disorders, including obesity, excess food intake and associated metabolic diseases such as diabetes. The analogues have good physical and chemical stability, good solubility, and a long duration of action, and are well suited for use in the form of a liquid formulation. | 2019-05-09 |
20190134160 | Pharmaceutical Combination for Use in Glycemic Control in Diabetes Type 2 Patients - The present invention refers to a pharmaceutical combination for use in glycemic control in diabetes type 2 patients. | 2019-05-09 |
20190134161 | COMPOSITION COMPRISING GLP-1 RECEPTOR AGONIST AND GLUCAGON RECEPTOR AGONIST AND APPLICATION THEREOF - The present invention provides a composition comprising a GLP-1 receptor agonist and a glucagon receptor agonist and an application of the composition. More specifically, the present invention provides a pharmaceutical composition comprising a pharmaceutically effective amount of the GLP-1 receptor agonist and the glucagon receptor agonist, wherein the GLP-1 receptor agonist and the glucagon receptor agonist independently form a conjugate with a hydrophilic polymer, or the GLP-1 receptor agonist and the glucagon receptor agonist jointly form a conjugate with the hydrophilic polymer. | 2019-05-09 |
20190134162 | Semaglutide in Cardiovascular Conditions - The present invention relates to the GLP-1 receptor agonist semaglutide for use in medicine. | 2019-05-09 |
20190134163 | ADRENOCORTICOTROPIC HORMONE-BASED PHARMACEUTICAL FORMULATIONS AND METHODS FOR FABRICATING AND USING THEREOF - Pharmaceutical compositions for treating, mitigating or preventing autoimmune diseases and associated conditions are described herein. Methods for fabricating the compositions and using them are also described. | 2019-05-09 |
20190134164 | MRNA THERAPY FOR POMPE DISEASE - The present invention provides, among other things, methods of treating Pompe disease, including administering to a subject in need of treatment a composition comprising an mRNA encoding acid alpha-glucosidase (GAA) at an effective dose and an administration interval such that at least one symptom or feature of Pompe disease is reduced in intensity, severity, or frequency or has delayed in onset. In some embodiments, the mRNA is encapsulated in a liposome comprising one or more cationic lipids, one or more non-cationic lipids, one or more cholesterol-based lipids and one or more PEG-modified lipids. | 2019-05-09 |
20190134165 | COMPOSITIONS AND METHODS FOR TREATING THYROID DISEASE - The present disclosure relates to a compound and method of administering such compound for treating a patient suffering from thyroid disease and various thyroid-related disorders, including hyperthyroid and hypothyroid. The unique combination of the composition is preferably administered orally. The composition is preferably comprised of at least selenium, zinc, iodine, manganese, molybdenum, ashwaganda root powder, polygonum root extract, a digestive enzyme such as DPP-IV, L-tyrosine and mullein leaf, in pre-determined amounts. The composition can further comprise a palliative agent, and can be provided in the form of a capsule or tablet. | 2019-05-09 |
20190134166 | Composition of proenzymes for cancer treatment - The present invention relates to compositions, methods, uses and kits for treating cancer. In particular, the invention relates to compositions and methods of treating cancer in a subject comprising administering chymotrypsinogen in certain amounts, for example a weight ratio of chymotrypsinogen:trypsinogen is greater than 1:1 but less than 4:1, thereby treating cancer. | 2019-05-09 |
20190134167 | CYCLOPHILIN 40 FOR REDUCTION OF NEUROTOXIC FIBRILS AND TREATMENT OF NEURODEGENERATIVE DISEASES - The present invention concerns the use of peptidyl-prolyl isomerase cyclophilin 40 (CyP40) for reduction of neurotoxic fibrils and treatment and prevention of neurodegenerative diseases associated with amyloid fibril aggregation. Aspects of the invention include compositions, methods, dosage forms, and kits for treating or preventing a neurodegenerative disease or condition associated with amyloid fibril aggregation in a human or animal subject, and for disaggregating neurofibrillary aggregates in vitro or in vivo, using CyP40, or a biologically active fragment thereof. | 2019-05-09 |
20190134168 | Combination, Therapeutic Uses And Prophylactic Uses - This invention relates to the therapeutic and prophylactic use of a combination including lactoperoxidase and at least one other component, with an isoelectric point of, or substantially above 6.8, and which are extracted from milk, to modulate the microbiome of an animal by selectively against at least one pathogenic microoganism. | 2019-05-09 |
20190134169 | DLL4-expressing cells and vaccine using the same - Methods are provided for generating DLL4-expressing immune cells. The invention also includes cellular compositions of dendritic and T cells produced by these methods. The immune cells of the invention can be used widely as components in many diagnostic and therapeutic systems, including improved vaccines to reduce the risk of graft versus host disease. | 2019-05-09 |
20190134170 | PCSK9 VACCINE AND METHODS OF USING THE SAME - A vaccine construct comprising an antigenic PCSK9 peptide and an immunogenic carrier, and methods of using the same that are effective to lower blood cholesterol levels in a mammal and treat dyslipidemias and related disease states in a mammal without the frequency of administration required by passive immunity strategies. | 2019-05-09 |
20190134171 | METHODS FOR TREATING AUTOIMMUNE DISEASE USING BIOCOMPATIBLE BIOABSORBABLE NANOSPHERES - The methods include selectively reducing or expanding T cells according to the antigenic specificity of the T cells using biocompatible bioabsorbable nanospheres. Therefore, the present invention can be used to reduce or eliminate pathogenic T cells that recognize autoantigens, such as beta cell specific T cells. As such, the present invention can be used to prevent, treat or ameliorate autoimmune diseases such as IDDM. Furthermore, the present invention can be used to expand desirable T cells, such as anti-pathogenic T cells to prevent, treat and/or ameliorate autoimmune diseases. | 2019-05-09 |
20190134172 | Therapeutically Triggering an Innate Immune Response in a Target Tissue - The invention provides therapeutic compositions that present an artificial repertoire of mammalian pattern recognition receptor (PRR) agonists, so that the pattern of PRR agonists recapitulates a distinct portion of a PRR agonist signature of a mammalian pathogen. The artificial repertoire of PRR agonists may be formulated together in a therapeutic vehicle for combined presentation to an innate immune cell resident in a target tissue in a mammalian host, and the vehicle adapted to deliver the PRR agonists to the target tissue, so as to modulate an immune response. | 2019-05-09 |
20190134173 | OVARIAN CANCER VACCINES - Provided herein are methods, kits and compositions for the treatment and/or prevention of ovarian cancer through the induction of an immune response against Anti-Mullerian Hormone Receptor, Type II (AMHR2). | 2019-05-09 |
20190134174 | COMPOSITIONS AND METHODS FOR TUMOR VACCINATION AND IMMUNOTHERAPY INVOLVING HER2/NEU - In certain embodiments, methods and compositions are provided for generating immune responses against tumor antigens such as a HER2/neu antigen or epitope. In particular embodiments there may be provided methods for constructing and producing recombinant adenovirus-based vector vaccines containing nucleic acid sequences encoding tumor antigens such as a HER2/neu antigen or epitope that allow for vaccinations in individuals with preexisting immunity to adenovirus. | 2019-05-09 |
20190134175 | EHRLICHIAL INVASIN FOR IMMUNIZTION, DIAGNOSIS, AND CELL DELIVERY - Disclosed are vaccines containing one or more immunogenic polypeptides derived from an EtpE protein from an | 2019-05-09 |
20190134176 | MYCOPLASMA HYOPNEUMONIAE VACCINE - This invention provides a protein-A or protein-G treated | 2019-05-09 |
20190134177 | CONJUGATE FOR VACCINATION AGAINST TYPHOID COMPRISING CHEMICAL CONJUGATE OF VI POLYSACCHARIDE AND FLAGELLIN, A PROCESS FOR PRODUCING THE SAME AND A COMPOSITION COMPRISING THE CONJUGATE - The present investigation relates to a conjugate comprising flagellin adjuvant covalently linked to Vi polysaccharide derived from | 2019-05-09 |
20190134178 | RAPID AND PROLONGED IMMUNOGENIC-THERAPEUTIC - The present invention shows that intranasal administration of E1/E3-defective adenovirus particles may confer rapid and broad protection against viral and bacterial pathogens in a variety of disease settings. Protective responses lasted for many weeks in a single-dose regimen in animal models. When a pathogen-derived antigen gene was inserted into the E1/E3-defective adenovirus genome, the antigen-induced protective immunity against the specific pathogen was elicited before the adenovirus-mediated protective response declined away, thus conferring rapid, prolonged, and seamless protection against pathogens. In addition to E1/E3-defective adenovirus, other bioengineered non-replicating vectors encoding pathogen-derived antigens may also be developed into a new generation of rapid and prolonged immunologic-therapeutic (RAPIT). | 2019-05-09 |
20190134179 | COMPOSITIONS CONTAINING COMBINATIONS OF BIOACTIVE MOLECULES DERIVED FROM MICROBIOTA FOR TREATMENT OF DISEASE - Compositions consisting of bioactive molecules derived from the microbiota of a mammal are provided herein. When administered orally with a colonic delivery system, the compositions are useful for the prophylaxis and treatment of diseases, in particular inflammatory, autoimmune and infectious diseases. The compositions comprise combinations of small molecules and bacterial antigens formulated in colonic delivery systems. Use of the compositions results in any or all of: induction of immune tolerance; strengthening of the gut mucosal barrier integrity; reduction of inflammation; and amelioration of a disease state caused by inflammation, an autoimmune reaction or an infectious agent. | 2019-05-09 |
20190134180 | NOVEL EUROPEAN PRRSV STRAIN - The present invention is related to improved modified live PRRS vaccines containing new PRRSV European strains of PRRSV and methods of use and manufacture of such vaccines. | 2019-05-09 |
20190134181 | IMMUNOMODULATING COMPOSITION FOR TREATMENT - Disclosed are therapeutic compositions and methods for inducing an immune response to human papillomavirus (HPV). More particularly, disclosed is a method for inducing an immune response in a subject by introducing and expressing a nucleic acid molecule encoding an immunogenic HPV antigen. | 2019-05-09 |
20190134182 | COMPOSITIONS AND METHODS FOR LIVE, ATTENUATED ALPHAVIRUS FORMULATIONS - Embodiments herein relate to compositions of and methods for live attenuated alphaviruses. In certain embodiments, a live, attenuated virus composition includes, but is not limited to, one or more live, attenuated alphaviruses and compositions to reduce inactivation and/or degradation of the live, attenuated alphavirus. In other embodiments, the live, attenuated virus composition may be a vaccine composition. In yet other compositions, a live, attenuated alphavirus composition may include HEPES buffer. In other embodiments, the HEPES buffer may further include a carbohydrate and gelatin and/or a salt. | 2019-05-09 |
20190134183 | RECOMBINANT ADENOVIRUS VECTORED FMDV VACCINES AND USES THEREOF - The present invention encompasses FMDV vaccines or compositions. The invention encompasses recombinant vectors encoding and expressing FMDV antigens, epitopes or immunogens which can be used to protect animals, in particular ovines, bovines, caprines, or swines, against FMDV. | 2019-05-09 |
20190134184 | ZIKA VIRAL ANTIGEN CONSTRUCTS - Compounds useful as components of immunogenic compositions for the induction of an immunogenic response in a subject against viral infection, methods for their use in treatment, and processes for their manufacture are provided herein. The compounds comprise a nucleic acid construct comprising a sequence which encodes a Zika virus antigen. A particular embodiment is a nucleic acid-based vaccine construct encoding a polypeptide comprising a full-length Zika virus prME antigen. A particular embodiment is a self-replicating RNA molecule comprising a construct encoding a polypeptide comprising a full-length Zika virus prME antigen. | 2019-05-09 |
20190134185 | UNIVERSAL INFLUENZA VACCINE BASED ON HETEROLOGOUS MULTIPLE M2E PROTEINS - Disclosed are universal influenza A vaccines capable of providing broader cross-protection. The vaccine contains a fusion protein comprising tandem repeats of heterologous M2e epitope sequences that have been molecularly and genetically designed to provide broad cross-protection. The fusion protein may be incorporated into virus-like particles (VLPs) or a replicating live attenuated influenza virus vaccine, and administered alone or in combination with other influenza vaccines. | 2019-05-09 |
20190134186 | INFLUENZA VACCINES WITH REDUCED AMOUNT OF EMULSION ADJUVANT - Influenza vaccines with oil-in-water emulsion adjuvants are known. The amount of emulsion adjuvant required for an influenza vaccine can be reduced, thereby allowing more vaccines to be made from a given amount of emulsion, and/or minimizing the amount of emulsion that has to be produced for a given number of vaccine doses. These vaccines can conveniently be made by mixing (i) an oil-in-water emulsion and (ii) an aqueous preparation of an influenza virus antigen. In one aspect, substantially equal volumes of components (i) and (ii) are used; in another aspect, an excess volume of component (ii) is used. When using substantially equal volumes, component (ii) has a hemagglutinin concentration of more than 60 μg per influenza virus strain per ml. Components (i) and (ii) can be presented in kit form. | 2019-05-09 |
20190134187 | MODIFIED RSV F PROTEINS AND METHODS OF THEIR USE - The present invention is generally related to modified or mutated respiratory syncytial virus fusion (F) proteins and methods for making and using them, including immunogenic compositions such as vaccines for the treatment and/or prevention of RSV infection. | 2019-05-09 |
20190134188 | Recombinant Newcastle Disease Virus Expressing an Immunomodulatory Protein as a Molecular Adiuvant - The present invention refers to recombinant Newcastle disease viruses (rNDV) having inserted a transcriptional unit foreign to its genome, which codifies for the synthesis of immunomodulatory proteins. These systems provide excellent protection results and significantly reduce the excreted viral load (post-vaccination and post-challenge) in poultry immunized several weeks after being challenged with a velogenic strain of the Newcastle virus. Additionally, said vaccines allow for the protection of poultry against other pathogenic agents during a long time period as they induce an increase of the immunomodulatory proteins level, which results in an enhancement of the immune response of the host and the development of an efficient humoral and cellular response. | 2019-05-09 |
20190134189 | TREATMENT OF PEANUT ALLERGY - The present invention relates to compositions, immunogenic or vaccine compositions and pharmaceutical compositions for the prevention or treatment of peanut allergy in humans. Furthermore, the invention provides methods for preventing or treating of peanut allergy in humans. | 2019-05-09 |
20190134190 | COMBINATION THERAPY WITH CPG TLR9 LIGAND - The present invention generally relates to an immunostimulatory combination comprising a first composition comprising a therapeutic vaccine and a second composition comprising one or more TLR9 ligand(s) such as CpG-containing oligonucleotide(s) as well as the use of such a first composition in combination with said second composition for treating a subject in need thereof. A specific embodiment is directed to the combination of a vectorized therapeutic vaccine encoding antigen(s) and a CpG-containing oligonucleotide such as Litenimod. Embodiments also include kits comprising such compositions as well as methods for treating, preventing or inhibiting diseases, in particular proliferative diseases or infectious diseases comprising administration of such first and second compositions. The invention is of very special interest in the field of immunotherapy, specifically for enhancing host's innate immune response, modifying local cytokine and chemokine profile and leukocyte populations at or around the treatment site and/or at or around the site of infection. | 2019-05-09 |
20190134191 | ALHYDROGEL-SODIUM CHLORIDE COMPOUND IMMUNOLOGIC ADJUVANT, PREPARATION METHOD AND USE THEREOF (As Amended) - The invention belongs to the field of biological medicine, in particular refers to an alhydrogel-sodium chloride compound immunologic adjuvant, preparation method and use thereof. The technical problem to be solved by the invention is to provide a well-behaved and novel immunologic adjuvant. The technical solution for solving the technical problem of the invention is to provide the use of sodium chloride in preparing immunologic adjuvant and the alhydrogel-sodium chloride compound immunologic adjuvant obtained on the basis thereof. The compound immunologic adjuvant mainly includes alhydrogel and sodium chloride. The alhydrogel-sodium chloride compound immunologic adjuvant of the invention is an excellent compound immunologic adjuvant, which can be used for various antigens, and provides a new and effective choice for the development and application of vaccines due to the advantages of simple and convenient use, low cost, strong immune activity, high clinical safety and the like. | 2019-05-09 |
20190134192 | TM4SF19 AS MARKER FOR DIAGNOSING OBESITY AND METHOD USING SAME - The diagnosis of obesity can be effectively carried out by using a composition for diagnosing obesity comprising a substance, which specifically couples to TM4SF19, a kit, and a method for diagnosing the obesity using the same. In addition, a candidate substance capable of treating obesity can be effectively screened in accordance with a method for screening a candidate substance for treating obesity, which inhibits the TM4SF19. | 2019-05-09 |
20190134193 | USE OF TAM RECEPTOR INHIBITORS AS IMMUNOENHANCERS AND TAM ACTIVATORS AS IMMUNOSUPPRESSORS - This disclosure concerns compositions and methods for immunoenhancement and/or immunosuppression. In certain embodiments, the disclosure concerns methods of using a TAM receptor inhibitor for immunoenhancement, for example as a vaccine adjuvant, for the treatment of sepsis, or for treating an immunocompromised subject. Also disclosed are methods of screening for immunoenhancing agents. In other embodiments, the disclosure concerns methods of using a TAM receptor agonist for immunosuppression, for example as a treatment for an autoimmune disorder, for the treatment of an allergy, or for treating graft-versus-host disease in a subject. Also disclosed are methods of screening for immunosuppressive agents. | 2019-05-09 |
20190134194 | SELECTIVELY ALTERING MICROBIOTA FOR IMMUNE MODULATION - The invention relates to methods of modulating immune cells in a patient by altering microbiota of the patient. The invention also relates to methods of modulating treatments or therapies in a subject organism by altering microbiota of the subject. The invention also relates to cell populations, systems, arrays, cells, RNA, kits and other means for effecting this. In an example, advantageously selective targeting of a particular species in a human gut microbiota using guided nucleic acid modification is carried out to effect the alteration. | 2019-05-09 |
20190134195 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF HUMAN PAPILLOMAVIRUS (HPV)-ASSOCIATED DISEASES - Methods and compositions for constructing and producing recombinant adenovirus-based vector vaccines are provided. In particular aspects, there are be provided compositions and methods involving adenovirus vectors comprising genes for target antigens, such as novel antigens of HPV E6 and/or HPV E7 for use in treatment methods that generate highly reactive anti-HPV and anti-tumor immune responses in subjects with preexisting immunity to adenovirus. | 2019-05-09 |
20190134196 | ETAR ANTIBODY, AND PHARMACEUTICAL COMPOSITIONS AND USE THEREOF - Provided herein are a stable solution formulation of an ET | 2019-05-09 |
20190134197 | ARTHROGENIC ALPHAVIRUS VACCINE - The invention relates to a vaccine comprising live attenuated recombinant alphavirus comprising mutated capsid protein. The invention also relates to a method of preventing a subject from contracting an alphaviral infection that would otherwise produce clinical signs of disease. In an embodiment the mutated capsid protein is Chikungunya virus (CHIKV) capsid protein having a mutated nucleolar localisation signal/sequence (NoLS), preferably the mutant NLS 101/95. | 2019-05-09 |
20190134198 | NANOSTRUCTURED CARRIERS FOR GUIDED AND TARGETED ON-DEMAND SUBSTANCE DELIVERY - Methods, systems, and devices are disclosed for fabricating and implementing nanoscale and microscale structured carriers to provide guided, targeted, and on-demand delivery of molecules and biochemical substances for a variety of applications including diagnosis and/or treatment (theranostics) of diseases in humans and animals. In some aspects, a nanostructure carrier can be synthesized in the form of a nanobowl, which may include an actuatable capping particle that can be opened (and in some implementations, closed) on demand. In some aspects, a nanostructure carrier can be synthesized in the form of a hollow porous nanoparticle with a functionalized interior and/or exterior to attach payload substances and substances for magnetically guided delivery and controlled release of substance payloads. | 2019-05-09 |
20190134199 | METHOD FOR THE PRODUCTION OF HYDROLYZED ALLERGENS - A pharmaceutical composition of hydrolyzed allergens and its use for treating, curing or preventing allergic reactions. The hydrolyzed allergens are prepared by:
| 2019-05-09 |
20190134200 | USE OF AN AMINO SUGAR AS PLASTICIZER - The present invention relates to the use of an amino sugar as plasticizer in formulations comprising a polymer as carrier for active ingredients, in particular for compositions which are intensively mixed by treatment in a melt extrusion and then formulated by suitable post-treatment. | 2019-05-09 |
20190134201 | STATIN-CONTAINING NANOPARTICLE PREPARATION FOR ENHANCING FUNCTION OF STEM CELLS FOR TREATING INFLAMMATORY DISEASE, AND FUNCTIONALLY ENHANCED STEM CELLS CONTAINING SAME FOR TREATING INFLAMMATORY DISEASE - A statin-encapsulated nanoparticle contains a bioabsorbable polymer and statin encapsulated in the nanoparticle. Suitable bioabsorbable polymers include a polylactic acid (PLA) polymer or a polylactic acid-glycolic acid (PLGA) copolymer. The statin-encapsulated nanoparticle can be used to enhance the function of a stem cell. The stem cell can be a stem cell for treating an inflammatory disease. | 2019-05-09 |
20190134202 | Liquid Injectable Copolymer - The invention provides liquid injectable copolymers of TMC and HTMC that are degradable in vivo. Degradation can be tailored by adjusting the amount of HTMC in the copolymer, the initial molecular weight of the copolymer, and the characteristics of the initiator used in its preparation. Specifically, the degradation rate increases as the amount of HTMC incorporated into the copolymer increases, as the molecular weight of the copolymer decreases, and as the hydrophobicity of the initiator decreases. Moreover, the degradation yields products such as glycerol and carbon dioxide that are non-toxic in vivo, and which will not cause a substantive change in tissue pH upon implantation in vivo. The copolymers may be used in applications such as drug delivery and as coatings. | 2019-05-09 |
20190134203 | TOPICAL TETRACYCLINE COMPOSITIONS - A topical therapeutic hydrophobic breakable composition includes a carrier comprising (a) about 60% to about 99% by weight of at least one hydrophobic oil; (b) at least one viscosity-modifying agents selected from the group consisting of a fatty alcohol, a fatty acid and a wax; and (c) a tetracycline antibiotic, characterized in that at least part of the tetracycline antibiotic is suspended in the composition; the viscosity of the composition is at least about 30% higher than the viscosity of the carrier without the tetracycline antibiotic; and is higher than the viscosity or the hydrophobic oil and the tetracycline antibiotic without the viscosity modifying agents. The tetracycline is chemically stable in the composition for at least six months; wherein more than about 90% of the tetracycline has not broken down. The composition is packaged as a breakable foam that breaks easily upon application or shear force. | 2019-05-09 |
20190134204 | SURFACTANT-FREE WATER-FREE FOAMABLE COMPOSITIONS, BREAKABLE FOAMS AND GELS AND THEIR USES - A substantially surface active agent free composition which includes a hydrophobic solvent, and/or a petrolatum, a paraffin wax and/or a fatty alcohol, a fatty acid and/or a wax and/or shea butter, with and without a propellant. A substantially surface active agent free composition, further comprising, a tetracycline antibiotic, or a vitamin D derivative, or one or more other active agents. A method of treatment using a substantially surface active agent free composition. | 2019-05-09 |
20190134205 | PYRROLOBENZODIAZEPINE CONJUGATES AND THEIR USE FOR THE TREATMENT OF CANCER - A conjugate of formula (I): L-(D | 2019-05-09 |
20190134206 | CARBOHYDRATE CONJUGATED RNA AGENTS AND PROCESS FOR THEIR PREPARATION - This disclosure relates to an improved process for the preparation of carbohydrate conjugates. The disclosure also relates to carbohydrate conjugated iRNA agents comprising these carbohydrate conjugates, which have improved purity and are advantageous for the in vivo delivery of the iRNA agents. | 2019-05-09 |
20190134207 | Nicotine Delivery Product, Related Uses and Oral Dosage Forms, and Methods of Production - The present invention relates to a nicotine delivery product comprising, or even consisting essentially of, a population of nicotine-loaded cation exchange resin particles, said population comprises at least 50% (w/w) particles having a size in the range of 90-300 micron which provides an improved nicotine stability to oral dosage forms comprising the nicotine delivery product. The invention furthermore relates to methods of producing the nicotine delivery product and the oral dosage forms and to the use of the nicotine delivery product. | 2019-05-09 |
20190134208 | MULTIFUNCTIONAL FORMS OF POLYOXAZOLINE COPOLYMERS AND DRUG COMPOSITIONS COMPRISING THE SAME - The present disclosure provides copolymers of 2-substituted-2-oxazolines possessing two or three reactive functional groups which are also chemically orthogonal. The copolymers described may be random copolymers, block copolymers or a mixture of random and block copolymer configurations. Furthermore, the present disclosure provides novel methods for synthesizing the above polymers and for conjugating to molecules such as targeting, diagnostic and therapeutic agents. | 2019-05-09 |
20190134209 | MULTIFUNCTIONALIZED BIOACTIVE POLYCAPROLACTONE - A multifunctionalized polycaprolactone polymer, a process for forming a multifunctionalized polycaprolactone polymer, and an article of manufacture comprising a material containing a multifunctionalized polycaprolactone polymer are disclosed. The multifunctionalized polycaprolactone polymer includes at least two functional groups. The process of forming the multifunctionalized polycaprolactone polymer includes forming a caprolactone monomer having at least two functional groups, and polymerizing the caprolactone monomer. Further, the article of manufacture includes a polycaprolactone polymer having at least two functional groups. | 2019-05-09 |
20190134210 | MACROMOLECULAR CHEMOTHERAPEUTICS - Embodiments of the invention are directed to a macromolecular chemotherapeutic. A non-limiting example of the macromolecular chemotherapeutic includes a block copolymer. The block copolymer can include a water-soluble block, a cationic block, and a linker, wherein the linker is connected to the water-soluble bock and the charged block. | 2019-05-09 |
20190134211 | CAR PEPTIDE FOR HOMING, DIAGNOSIS & TARGETED THERAPY FOR PULMONARY AND FIBROTIC DISORDERS - Disclosed are compositions and methods useful for delivering targeted therapies for pulmonary diseases, fibrotic disorders and cancer. The compositions and methods are based on peptide sequences that selectively bind to and home to diseased tissue and enable targeted therapies to effect a beneficial therapeutic result. The disclosed targeting is useful for delivering therapeutic and detectable agents to diseased tissue in an animal. | 2019-05-09 |
20190134212 | SUPRAMOLECULAR PROTEIN ASSEMBLIES WITH ADVANCED FUNCTIONS AND SYNTHESIS THEREOF - The present invention discloses stimuli-sensitive protein conjugate which can make supramolecular protein assemblies and methods for using the same. The present invention provides simple and rational process for construction of said stimuli-sensitive spherical protein assemblies through supramolecular chemical strategy. | 2019-05-09 |
20190134213 | BICYCLIC PEPTIDE-TOXIN CONJUGATES SPECIFIC FOR MT1-MMP - The present invention relates to drug conjugates comprising bicyclic peptides specific for MT1-MMP conjugated to one or more effector and/or functional groups which have utility in targeted cancer therapy. | 2019-05-09 |
20190134214 | GLP-1 Receptor Ligand Moiety Conjugated Oligonucleotides and Uses Thereof - The present embodiments provide compounds and methods for targeting cells expressing GLP-1 receptor. | 2019-05-09 |
20190134215 | COMBINATION OF CD33 ANTIBODY DRUG CONJUGATES WITH CHEMOTHERAPEUTIC AGENTS - This invention relates to treatment of cancer using a CD33 antibody drug conjugate in combination with chemotherapeutic agents. | 2019-05-09 |
20190134216 | ANTI-EGFR ANTIBODIES AND ANTIBODY DRUG CONJUGATES - The invention relates to anti-epidermal growth factor (EGFR) antibodies and antibody drug conjugates (ADCs), including compositions and methods of using said antibodies and ADCs. | 2019-05-09 |
20190134217 | COMPOSITIONS AND METHODS FOR THE DEPLETION OF CD117+ CELLS - The invention provides compositions and methods useful for the depletion of CD117+ cells and for the treatment of various hematopoietic diseases, metabolic disorders, cancers, and autoimmune diseases, among others. Described herein are antibodies, antigen-binding fragments, ligands, and conjugates thereof that can be applied to effect the treatment of these conditions, for instance, by depleting a population of CD117+ cells in a patient, such as a human. The compositions and methods described herein can be used to treat a disorder directly, for instance, by depleting a population of CD117+ cancer cells or autoimmune cells. The compositions and methods described herein can also be used to prepare a patient for hematopoietic stem cell transplant therapy and to improve the engraftment of hematopoietic stem cell transplants by selectively depleting endogenous hematopoietic stem cells prior to the transplant procedure. | 2019-05-09 |
20190134218 | COMPLEX OF ADENOVIRUS AND PAMAM-PEG-ERBITUX, AND USE THEREOF - The present invention relates to a complex of an antitumor adenovirus coated with ErbB-PEG-PAMAM and the use thereof. When using the complex of the present invention, a tumor cell-specific gene transfer effect by an excellent tumor cell infiltration ability is excellent, hepatotoxicity is low, a blood flow retention time is prolonged. Thus, the complex of the present invention can be used as a pharmaceutical composition for the treatment of a tumor and a gene therapy agent which can be administered systemically. | 2019-05-09 |
20190134219 | INHIBITION OF SPONTANEOUS METASTASIS VIA PROTEIN INHIBITORS OF CYSTEINE PROTEASES - Two disparate biological mechanisms which predispose to the dissemination and metastases of solid tumors is described. The treatment of metastatic lesions via topical and transdermal administration of therapeutic agents, such as Type 1 Cystatins, through intact skin, is directed to the inhibition of lysosomal cysteine cathepsin proteolytic enzymatic degradation of the extracellular matrix | 2019-05-09 |
20190134220 | Conjugates and Conjugating Reagents - A conjugate of a protein or peptide conjugated to a therapeutic, diagnostic or labelling agent via a linker, in which the linker includes a protein or peptide bonding portion having the general formula: | 2019-05-09 |
20190134221 | CRISPR/CAS-RELATED METHODS AND COMPOSITIONS FOR TREATING DUCHENNE MUSCULAR DYSTROPHY - Disclosed herein are vectors that targets a dystrophin gene, encoding at least one Cas9 molecule or a Cas9 fusion protein, and at least one gRNA molecule (e.g., two gRNA molecules), and compositions and cells comprising such vectors. Also provided are methods for using the vectors, compositions and cells for genome engineering (e.g., correcting a mutant dystrophin gene), and for treating DMD. | 2019-05-09 |
20190134222 | PHARMACEUTICAL COMPOSITION CONTAINING A STABILISED mRNA OPTIMISED FOR TRANSLATION IN ITS CODING REGIONS - The present invention relates to a pharmaceutical composition comprising a modified mRNA that is stabilised by sequence modifications and optimised for translation. The pharmaceutical composition according to the invention is particularly well suited for use as an inoculating agent, as well as a therapeutic agent for tissue regeneration. In addition, a process is described for determining sequence modifications that promote stabilisation and translational efficiency of modified mRNA of the invention. | 2019-05-09 |